Bamlanivimab Plus Etesevimab Cuts COVID-19 Hospitalization, Deaths
The combination therapy reduced the risk of hospitalization or death by 70%.
All articles by Diana Ernst, RPh
Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation
The study was conducted by Pfizer and the University of Texas Medical Branch.
Experts Weigh In on the Best Diets for 2021
An expert panel assessed 39 diets to come up with the final results, examining the evidence behind each diet’s claims.
Counterfeit HIV Drug Identified in Three US Pharmacies
The counterfeit products were procured from unauthorized distributors.
RediTrex Now Available for RA, pJIA, Psoriasis Treatment
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Abrocitinib Associated With Less Flare in Atopic Dermatitis Trial
The JADE REGIMEN trial was a responder-enriched, placebo-controlled withdrawal study that included a 12-week open-label run-in period.
Combination Antibody Therapy Reduces Viral Load, COVID-19 Hospitalizations
An interim analysis of the phase 2 study evaluated the combination therapy in recently diagnosed patients with mild to moderate COVID-19.
AstraZeneca Pauses COVID-19 Vaccine Trials
In a statement, the Company noted that the actions being taken are considered “routine” when an unexplained illness is reported in a clinical trial.
Remdesivir EUA Expanded to Include All Hospitalized COVID-19 Patients
Previously, the EUA limited use to patients with severe COVID-19 disease.
Emergency Use Authorization Issued for COVID-19 Convalescent Plasma
The EUA was based on historical evidence indicating some effectiveness with convalescent plasma use in previous outbreaks of respiratory viruses, preclinical data, results from small clinical trials, and data from the National Expanded Access Treatment Protocol sponsored by the Mayo Clinic.
-
Loading...
-
Loading...
Next post in Practice Management
